Drugs / Plasmalyte
Plasmalyte
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT04102371 | Aug 2020 → Dec 2025 | — | Children's Hospital of Philadelphia | Completed | Missed primary |
| Phase 3 | NCT03118362 | Aug 2017 → Sep 2018 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02875873 | May 2017 → Mar 2020 | acute kidney injury | Hospital do Coracao | Completed | Missed primary |
| Phase 3 | NCT02691676 | Jan → Dec 2014 | disorder of acid-base balance | University Hospital Olomouc | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT04688645 | May 2020 → Dec 2022 | acute pancreatitis | University Hospital Rijeka | Unknown | No outcome recorded |
| Phase 4 | NCT00885404 | Feb → Aug 2009 | — | Austin Health | Unknown | Met primary |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT06076330 | Sep 2023 → Aug 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT06097923 | Nov 2021 → Dec 2022 | — | Seoul St. Mary's Hospital | Completed | Missed primary |
| — | NCT02936167 | Sep 2016 → Feb 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1/2 | NCT01087853 Comparator | Mar 2010 → Mar 2011 | disorder of acid-base balance, water intoxication | University of Nottingham | Completed | No outcome recorded |
| Phase 2 | NCT03366220 Comparator | Mar 2018 → Sep 2019 | infectious disease with sepsis | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05355974 Background | Aug 2022 → Jul 2024 | hypotensive disorder, orthostatic hypotension 2, respiratory failure | Wright State University | Completed | No outcome recorded |
| Phase 4 | NCT07189091 Comparator | Oct 2025 → Apr 2028 expected | — | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 4 | NCT06080178 Comparator | Nov 2023 → Oct 2026 expected | — | Algemeen Ziekenhuis Maria Middelares | Recruiting | No outcome recorded |
| Phase 4 | NCT03373318 Comparator | Jan 2018 → Aug 2019 | acute kidney injury | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02528448 Comparator | Mar 2015 → Feb 2016 | poisoning | Regional Hospital Holstebro | Unknown | No outcome recorded |
| Phase 4 | NCT02312999 Comparator | Feb 2015 → Dec 2017 | — | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02135146 Comparator | Jan 2014 → Sep 2016 | acute kidney injury, hypotensive disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02463175 Background | Jun 2015 → Jan 2016 | acute kidney injury, scoliosis | University of British Columbia | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma-Lyte | “In Phase A, 12 subjects will receive 2 litres of 0.9% saline BP (Baxter Health Care, Thetford, UK) or Plasmalyte® (Baxter Health Care, Thetford, UK).” NCT01087853 ↗19“Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization” NCT04688645 ↗ “Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines.” NCT03366220 ↗ “a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte).” NCT06097923 ↗ |
| Known as | Plasma-Lyte 148 | “patients instead received a lactated solution (Hartmann solution), a balanced solution (Plasma-Lyte 148), and chloride-poor 20% albumin.” PMID 23073953 ↗ Oct 2012 |
| Known as | Plasmalyte (Baxter Healthcare) | “Plasmalyte (Baxter Healthcare)” NCT02691676 ↗ |
| Modality | Other / unclassified | “A baseline crystalloid infusion (plasmalyte®)” NCT02312999 ↗ |
| Route | Intravenous | “This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr.” NCT02135146 ↗ |